| Symbol | BDTX |
|---|---|
| Name | BLACK DIAMOND THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | ONE MAIN STREET,10TH FLOOR, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 252-0848 |
| Fax | — |
| — | |
| Website | https://www.blackdiamondtherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. Additional info from NASDAQ: |
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Read more(30% Negative) BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Reports Q1 2026 Financial Results
Read moreBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Read moreNew Form S-8 - Black Diamond Therapeutics, Inc. <b>Filed:</b> 2026-03-16 <b>AccNo:</b> 0001104659-26-028461 <b>Size:</b> 195 KB
Read moreNew Form 10-K - Black Diamond Therapeutics, Inc. <b>Filed:</b> 2026-03-16 <b>AccNo:</b> 0001701541-26-000009 <b>Size:</b> 8 MB
Read moreBlack Diamond Therapeutics to Participate in Upcoming Investor Conferences
Read moreBehbahani Ali 🟢 acquired 5.2K shares of Black Diamond Therapeutics, Inc. (BDTX) at $2.76 Transaction Date: Dec 12, 2025 | Filing ID: 319303
Read moreRaman Prakash 🟢 acquired 4.7K shares of Black Diamond Therapeutics, Inc. (BDTX) at $2.76 Transaction Date: Dec 12, 2025 | Filing ID: 000007
Read moreNew Form EFFECT - Black Diamond Therapeutics, Inc. Filed: 2025-12-03 AccNo: 9999999995-25-003511 Size: 1 KB
Read more(90% Positive) BLACK DIAMOND THERAPEUTICS, INC. (BDTX) Announces Enrollment Update for mutations Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| temozolomide (TMZ) | DRUG | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib in combination with temozolomide | DRUG | Phase PHASE2 | Glioblastoma (GBM) | RECRUITING | NCT07326566 |
| silevertinib (BDTX-1535) monotherapy | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05256290 |
| BDTX-189 | DRUG | Phase PHASE1 | Solid Tumor | TERMINATED | NCT04209465 |